Search Results
Your search for ,amp matches 4215 pages
Showing 2951 - 3000For the Impoverished, Health Care Is a Luxury
Cancer is the second leading cause of death worldwide, and the global burden is on an inexorably upward trajectory. For the year 2012, there were 14.1 million new cancer cases and 8.2 million cancer-related deaths worldwide.1 It is predicted that by the year 2035, there will be 23.9 million new...
Genetic Variant May Significantly Lower Risk of Breast Cancer in Women With History of Preeclampsia
Researchers have demonstrated that women with a history of preeclampsia have as much as a 90% decrease in breast cancer risk if they carry a specific common gene variant. Further studies are now underway to determine the mechanism of this protection in an effort to develop new breast cancer...
Androgen-Deprivation Therapy May Be Associated With Higher Risk of Heart Failure in Early-Stage Prostate Cancer
Men with localized prostate cancer who received androgen-deprivation therapy were at significantly higher risk of heart failure than men who did not receive this therapy, according to a Kaiser Permanente study published by Haque et al in the British Journal of Cancer. In the past,...
Clinical Genomics Implements QIAGEN’s Tube Collection Technology for Colorectal Cancer Recurrence Assay
On August 21, Clinical Genomics announced they have implemented QIAGEN’s PAXgene circulating cell-free DNA tube blood sample collection in its Colvera colorectal cancer recurrence assay. Colvera, an integrated liquid biopsy solution, is designed to enable easy and accurate...
Medical Costs and HPV Vaccination in Oropharyngeal Cancer
According to the Centers for Disease Control and Prevention, human papillomavirus (HPV)-related cancers, including oropharyngeal, vulvar, cervical, vaginal, penile, anal, and rectal cancers, have increased in recent years, with oropharyngeal cancer the most common HPV-related cancer—from 2008 ...
ASCO, CCF Congratulate 2017 Grant and Award Recipients
The Conquer Cancer Foundation of ASCO (CCF) presented more than $6.3 million in grants and awards to 247 promising oncology researchers at the 2017 ASCO Annual Meeting. CCF and ASCO congratulate the recipients on their contributions to the field of oncology and offer their profound thanks to the...
Patricia Ganz, MD, Appointed Editor-in-Chief of JNCI
ON JULY 1, Patricia Ganz, MD, assumed editorial leadership of JNCI: Journal of the National Cancer Institute. As Editor-in-Chief, she is also responsible for JNCI Monographs. Dr. Ganz is Director of Cancer Prevention & Control Research at the University of California Los Angeles (UCLA)’s...
Fighting Misinformation in HPV-Related Cancer Prevention
FAKE NEWS, junk science, and alternative facts seem pervasive in our current culture, to the detriment of important, verified scientific advancements. One area where this is quite evident is the vaccine against human papillomavirus (HPV). Although we have had a safe, effective vaccine since 2006...
Hospice and Palliative Medicine Fellowship Created at Fox Chase Cancer Center
The Pain & Palliative Care Program at Fox Chase Cancer Center is offering a new Hospice and Palliative Medicine fellowship in partnership with the Hospice of the Visiting Nurse Association of Greater Philadelphia and Temple University Hospital. The 1-year program is approved by the...
Genomic Characteristics and Immune Infiltration in Triple-Negative Breast Cancer
In a study reported in JAMA Oncology, Karn et al found that triple-negative breast cancers with high immune gene expression levels were characterized by lower clonal heterogeneity, reduced copy number alterations, and lower somatic mutation and neoantigen loads. Study Details In the study, DNA...
ASCO Tackles the Issue of the High Cost of Cancer Drugs
In July, ASCO issued a comprehensive set of recommendations to remedy the problem of escalating drug pricing on cancer therapies.1 ASCO’s position statement comes at a time when new cancer drugs are routinely priced at $100,000 a year or more—imatinib (Gleevec) costs up to $146,000 a year2—causing...
The X-Ray Era 1901–1915
The text and photograph on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photo below is from the volume titled “The X-Ray Era: 1901–1915.” The photograph appears...
Syed Abutalib, MD, Appointed to Education Committee for ASBMT
THE CANCER TREATMENT CENTERS OF AMERICA issued congratulations to Syed Abutalib, MD, in July for being appointed to the Education Committee for the American Society for Blood and Marrow Transplantation (ASBMT). Dr. Abutalib is Assistant Director, Stem Cell Transplant & Cell Therapy Program at...
First Oncologist Elected AMA President, Barbara L. McAneny, MD, Advocates for Access to Health Care for Everyone
Since the founding of the American Medical Association (AMA) in 1847, Barbara L. McAneny, MD, is the fourth woman and first oncologist to be elected President of the venerable medical association. “I’m a generic Midwesterner. I was born in Missouri and raised in Madison County, Illinois, and went...
Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Advanced Melanoma
In the phase IB KEYNOTE-029 study, standard-dose pembrolizumab (Keytruda) plus reduced-dose ipilimumab (Yervoy) produced high response rates in patients with advanced melanoma. These results were reported by Long et al in The Lancet Oncology. Study Details In the study, 153 patients with...
Poor Social Functioning in Adolescent and Young Adult Cancer Survivors
A new study indicates many young adults who survived the disease struggle with “getting back to normal” as much as 2 years after their initial diagnosis. The longitudinal study, published by Husson et al in Cancer, is among the first seeking to understand the social functioning among...
Proposed 2018 QPP Rule Adds Flexibility, but Questions on Medicare Part B Drugs Provision Remain
THE CENTERS for Medicare & Medicaid Services (CMS) released its proposed rule outlining changes to the Quality Payment Program (QPP) for 2018. ASCO is encouraged by the flexibility added to QPP in the proposal, which includes an extended transition period through the end of 2018 for both the...
Key Leadership in Place in Trump Administration
IN JUNE 2017, President Trump installed the final member of his cancer care leadership team, Norman “Ned” Sharpless, MD, who will serve as the Director of the National Cancer Institute. Director Sharpless is an accomplished researcher with experience leading a wide range of clinical and...
ASCO-AACI’s Best Practices in Cancer Clinical Trials Initiative: Streamlining Adverse Events Reporting and Research Community Forum Activities
Research sites and investigators face an ever-increasing number of challenges in the conduct and management of cancer clinical trials. Many of these challenges stem from the multitude of requirements for clinical trials that sponsors and regulatory and administrative agencies have set. In...
Mike Heller, PhD, Joins OHSU Knight Cancer Institute
THE OREGON Health & Science University (OHSU) Knight Cancer Institute announced that bioengineering and technology expert Mike Heller, PhD, will join the Institute’s Cancer Early Detection Advanced Research Center (CEDAR) to lead its technology efforts. A leader with more than 53 issued...
Solange Peters, MD, PhD, Elected 2020–2021 ESMO President
THE EUROPEAN SOCIETY for Medical Oncology (ESMO) has announced that the President of the Society for the 2020–2021 term will be Solange Peters, MD, PhD, Head of the Medical Oncology Service and Chair of Thoracic Oncology, Oncology Department at the Centre Hospitalier Universitaire Vaudois in...
Pembrolizumab Is Active in Platinum- and Cetuximab-Refractory Head and Neck Cancer
IN THE PHASE II KEYNOTE-055 trial, pembrolizumab (Keytruda) was found to produce durable responses in patients with platinum- and cetuximab (Erbitux)-refractory head and neck squamous cell carcinoma.1 Results of the trial were reported by Joshua Bauml, MD, of the University of Pennsylvania,...
Insurance Approval Rates for Enrollment in Oncology Clinical Trials Increased Under Affordable Care Act
The Patient Protection and Affordable Care Act (ACA) of 2010 was the first federal law to mandate that group health insurance plans and state-licensed insurance issuers provide coverage of standard-of-care costs for patients enrolled in approved clinical trials, effective on January 1, 2014. Under...
Impact of Health Insurance and Sociodemographic Status on Survival for AYAs With Cancer
According to the National Cancer Institute, cancer is the leading cause of disease-related death among adolescents and young adults (AYAs) between the ages of 15 and 39. And although cancer survival among this age group is more than 80%, AYAs have not experienced the same improvements in relative...
A Great IDEA: Celebrating 15 Years of the International Development and Education Award
In 2017, ASCO and the Conquer Cancer Foundation of ASCO are proud to celebrate the 15th anniversary of the International Development and Education Award (IDEA). The IDEA program supports the professional development of early-career oncologists in low- and middle-income countries around the world....
Pembrolizumab Is Highly Active in Relapsed/Refractory Classical Hodgkin Lymphoma
AS REPORTED in the Journal of Clinical Oncology by Robert Chen, MD, of City of Hope National Medical Center, and colleagues, the phase II KEYNOTE-087 trial has shown that the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda) is highly active in patients with relapsed/...
ASCO’s New MACRA Decision Tree Tool Helps Determine Which QPP Reporting Requirements Apply to Your Practice
Believe it or not, we’re halfway through the 1st year of the Quality Payment Program (QPP). ASCO, the Centers for Medicare & Medicaid Services (CMS), and other stakeholders have released guidance on successfully complying with QPP, but tailored information addressing a practice’s specific...
Autologous and Allogeneic Hematopoietic Cell Transplantation
HERE ARE SEVERAL ABSTRACTS selected from the proceedings of the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting clinical trials on autologous and allogeneic hematopoietic cell transplantation for various hematologic malignancies. Additional selected...
James Francis McCarthy
The family and staff of Harborside Press mourn the loss of former colleague, and forever friend James F. McCarthy, who passed away after a brief illness on June 23, 2017. Born in Brooklyn, New York, on January 7, 1929, to John A. and Eda K. McCarthy, Jim was a graduate of Brooklyn Preparatory High ...
Dacomitinib Outperforms Gefitinib in EGFR-Positive NSCLC
DACOMITINIB, a second-generation epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitor, outperformed gefitinib (Iressa) as first-line treatment for EGFR-positive advanced non–small cell lung cancer (NSCLC) in the phase III ARCHER 1050 study.1 Dacomitinib improved...
Adding Sorafenib to Transarterial Chemoembolization in Hepatocellular Carcinoma
As reported in The Lancet Gastroenterology & Hepatology by Meyer et al, the UK phase III TACE 2 trial has shown no progression-free survival benefit with the addition of sorafenib (Nexavar) to transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. The trial was...
Pediatric Cancer Pain May Be Misunderstood and Largely Undertreated
Cancer pain in children poses certain unique challenges. Over the past decade, insightful research into pediatric cancer pain has focused on pain management that incorporates nonopioid therapies into standard care. To shed light on this important issue, The ASCO Post spoke with Christine T....
Scalp Cooling to Prevent Chemotherapy-Induced Alopecia: Is It Now Ready for Prime Time?
In oncology, sometimes we forget about the small, everyday things that can significantly impact a patient’s life. When patients are explained the side effects of chemotherapy and chemotherapy-induced alopecia, most women will cry or become visibly upset. When a woman loses her hair, it represents...
ESMO World GI 2017: Study Explores Association of Mediterranean Diet Components With Advanced Colorectal Polyps
The benefits of a Mediterranean diet are well known when it comes to colorectal protection, but it’s hard to know specifically what elements of the diet are the healthiest. Now a new study, presented by Fliss Isakov et al at the ESMO 19th World Congress on Gastrointestinal Cancer, suggests...
EHA 2017: Half of Chronic-Phase Philadelphia Chromosome–Positive CML Patients Stay in Treatment-Free Remission 2 Years After Stopping Nilotinib
New data from two clinical trials—ENESTfreedom and ENESTop—demonstrates that approximately half of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia (CML) in the chronic phase, were able to maintain treatment-free remission after stopping treatment with ...
Secondhand Smoke Exposure Among Nonsmoking Cancer Survivors
According to the Centers for Disease Control and Prevention (CDC), tobacco use and exposure accounts for about one-third of all cancer-related deaths in the United States. Moreover, exposure to secondhand tobacco smoke is attributable to more than 7,000 lung cancer–related deaths each year in ...
ASCO Launches CENTRA: A New Hub for Cancer Care Research, Data, and Analysis
ASCO has announced the launch of its Center for Research & Analytics (CENTRA), which aims to make an array of cancer data available to the oncology community and provide consultation and support for research and analysis. To help guide the program, ASCO has appointed Elizabeth Garrett-Mayer,...
Positive Results for APHINITY, but Value of Benefit of Dual HER2 Blockade Questioned
The results of the long-awaited APHINITY trial are in, and although the phase III study met its primary endpoint, it failed to establish dual HER2 blockade as the optimal adjuvant treatment for early HER2-positive breast cancer. After 3 years of follow-up, the addition of pertuzumab (Perjeta) to...
ASCP/CAP/AMP/ASCO Colorectal Cancer Biomarker Guideline: A Clinician's Perspective
The joint American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and ASCO guideline reported by Sepulveda et al, and reviewed in this issue of The ASCO Post, represents a collaboration of three pathology societies and ASCO ...
ASCP/CAP/AMP/ASCO Guideline on Molecular Biomarkers in Colorectal Cancer
As reported in the Journal of Clinical Oncology by Antonia R. Sepulveda, MD, PhD, of Columbia University, and colleagues, a joint guideline on the use of molecular biomarkers for evaluation of colorectal cancer has been developed by an expert panel from the American Society for Clinical Pathology...
ICML 2017: 3-Year Follow-up Showed Fourfold Progression-Free Survival Benefit With Ibrutinib vs Temsirolimus at First Relapse in Mantle Cell Lymphoma
Three-year follow-up data from the phase III RAY study in patients with relapsed or refractory mantle cell lymphoma were presented at the 14th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. These results demonstrated that the subset of patients treated with ibrutinib...
ASTRO Issues Guideline for Use of Stereotactic Radiation in Early-Stage Lung Cancer
The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the use of stereotactic body radiation therapy (SBRT) in early-stage lung cancer. While SBRT is the current standard of care for peripherally located tumors in patients who cannot undergo surgery, the new...
PD-L2 Expression and Clinical Response to Pembrolizumab in Head and Neck Cancer
A study assessing the prevalence and distribution of programmed cell death ligand 2 (PD-L2) in human tumor samples across seven cancer indications, including renal cell carcinoma, bladder, melanoma, non–small cell lung cancer, triple-negative breast cancer, gastric carcinoma, and head and...
Vital Options International Introduces Free eBook, The Cancer Concierge
Between the onslaught of bills and the endless stream of tests and appointments, managing cancer treatment can be overwhelming. There needs to be a good organizing system in place from the very first oncologist appointment. No one understood this better than the Founder of Vital Options ...
Pembrolizumab in Solid Tumors With Mismatch-Repair Deficiency
As reported by Le et al in Science, pembrolizumab (Keytruda) was found to be active across a range of solid tumors with mismatch-repair (MMR) deficiency. Pembrolizumab was recently approved for treatment of patients with unresectable or metastatic microsatellite instability–high (MSI-H) or...
Fred & Pamela Buffett Cancer Center Dedicated at UNMC
The University of Nebraska Medical Center (UNMC) and its clinical partner, Nebraska Medicine, has officially dedicated the new Fred & Pamela Buffett Cancer Center in Omaha. Joe Biden, the former two-term Vice President who headed a national Cancer Moonshot Task Force, served as keynote speaker...
ASCO COME HOME Offers Direct Support to Practices Transitioning to Quality Payment Program
ASCO is making it easier for practices to understand and prepare for the transition to the Quality Payment Program (QPP) in the years ahead with its ASCO COME HOME initiative. ASCO COME HOME provides readiness assessment tools to help practices evaluate whether or not they are ready to transition...
Combination Therapy With Pembrolizumab in Metastatic Nonsquamous NSCLC
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 10, 2017, pembrolizumab (Keytruda) was granted accelerated...
Selected Novel Agents in Development for Multiple Myeloma
Here are several abstracts selected from the proceedings of the 2016 America Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics for the development for patients with relapsed or refractory multiple myeloma. For full details of these study abstracts, visit...
Special Awards and Lectures Presented During 2017 ASCO Annual Meeting
Recipients of ASCO’s Notable Awards and Lectures are individuals who have made extraordinary contributions to the research and treatment of patients with cancer. These individuals were honored during several special sessions held during ASCO’s 53rd Annual Meeting, where more than 30,000 physicians, ...
